




Amarin Corporation plc  
Investor Relations Department  
2 Pembroke House, Upper  
Pembroke  
Street 28-32  
Dublin 2  
Ireland

[Visit IR website](#)   
[Sign-up for Email alerts](#) 

**NASDAQ: AMRN**

Last Trade:	3.70
Trade Time:	4:00 PM ET Feb 23, 2018
Change:	0.03  (+0.817%)
Day Range	3.63 - 3.72
52-Week Range	2.85 - 4.60
Volume	898,327

Stock information is provided by eSignal,  
stock charts provided by EDGAR Online.  
Stock data is delayed approximately 20  
minutes.

## Company Profile

Amarin is conducting a cardiovascular outcomes study designed to evaluate the efficacy of Vascepa® in reducing cardiovascular events in a high-risk patient population on statin therapy called the REDUCE-IT trial.

Amarin is headquartered in Dublin, Ireland. Amarin's U.S. office is in Bedminster, New Jersey. Amarin is listed in the U.S. on NASDAQ (symbol: "AMRN").

... [\(more\)](#)

## Stock Performance



## Press Releases [\[ View all \]](#)

*Feb 20, 2018*

[Amarin to Report Fourth Quarter and Full Year 2017 Results and Host Conference Call on February 27th, 2018](#)

*Jan 30, 2018*

[Amarin Prices Public Offering of American Depositary Shares](#)

*Jan 29, 2018*

[Amarin Announces Proposed Public Offering of American Depositary Shares](#)

*Jan 23, 2018*

[Amarin's REDUCE-IT Cardiovascular Outcomes Study Reaches 90% Mark for Reported Primary Events](#)

*Jan 17, 2018*

[Amarin Announces Commencement of VASCEPA® Clinical Development in Mainland China](#)

## Upcoming Events [\[ View all \]](#)

*Feb 27, 2018 8:00 AM ET*

[Amarin Q4 Results Conference Call](#)

## Financials [\[ View all \]](#)

[Third Quarter Financial Results](#)

*Mar 1, 2017*

[Annual Report \(10-K\)](#)

*Apr 21, 2017*

[Proxy Statement \(DEF 14A\)](#)

*Nov 1, 2017*

[Quarterly Report \(10-Q\)](#)

*Aug 2, 2017*

[Quarterly Report \(10-Q\)](#)

*May 3, 2017*

[Quarterly Report \(10-Q\)](#)